A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers

Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Goff, Laura W., Cardin, Dana B., Whisenant, Jennifer G., Du, Liping, Koyama, Tatsuki, Dahlman, Kimberly B., Salaria, Safia N., Young, Ruth T., Ciombor, Kristen K., Gilbert, Jill, Smith, Stephen James, Chan, Emily, Berlin, Jordan
Format: Artigo
Langue:Inglês
Publié: Springer US 2016
Sujets:
Phase I Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://ncbi.nlm.nih.gov/pubmed/27853997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0406-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires